Neoplasms

All Conditions

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Gland and Hormone Related Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Nasopharyngeal Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Head and Neck Neoplasms

Nasopharyngeal Carcinoma

Mouth Neoplasms

Oropharyngeal Neoplasms

Salivary Gland Neoplasms

Laryngeal Diseases

Laryngeal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Endocrine System Diseases

Endocrine Gland Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Respiratory Tract Diseases

Mouth Diseases

Salivary Gland Diseases

Respiratory Tract Neoplasms

Oral Cancer

Laryngeal Cancer

Hypopharyngeal Cancer

Lip and Oral Cavity Cancer

The aim is to differentiate between patients with head and neck cancer from those without based on a blood sample.

The aim is to identify recurrence through serial monitoring patients with blood samples.

The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA

Liquid biopsy

Christian Grønhøj, MD, Ph.D

Christian Von Buchwald, MD, DMSc

This study investigates if head and neck squamous cell carcinoma can be tracked with cell-free tumor DNA, RNA or HPV-DNA, in blood samples from patients referred with suspicion of cancer, and if it can be used in detecting recurrence in patients already diagnosed and treated for head and neck squamous cell carcinoma.

Cell-free Tumor DNA in Head and Neck Cancer Patients

Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer

The primary outcome is to measure the percentage of head and neck squamous cell carcinomas that can be detected using a liquid biopsy (blood sample)

The primary outcome is to measure the percentage of recurrence in head and neck cancer patients through serial monitoring with liquid biopsies (blood sample)

Copenhagen University Hospital, Denmark

Department of Otorhinolaryngology, Head and Neck Surgery and Audiology

Christian von Buchwald

Clinical Professor

Early-stage OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).

Early-stage OPC patients treated with radiotherapy (RT) according to proper indications (CSCO 2021 and NCCN 2021).

Advanced OPC patients treated with chemoradiotherapy (CRT) according to proper indications (CSCO 2021 and NCCN 2021).

Advanced OPC patients treated with surgery according to proper indications (CSCO 2021 and NCCN 2021).

Advanced OPC patients treated with neoadjuvant treatment according to proper indications (CSCO 2021 and NCCN 2021).

The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.

Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery (e.g., CO2 laser resection), and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.

Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., extranodal extension, perineural invasion or vascular invasion).

Surgery for early-stage OPC

The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.

Early-stage OPC patients (T1-2,N0) enrolled in this group will be treated with RT.

RT for early-stage OPC

The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.

Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with CRT.

CRT for advanced OPC

The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.

Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with surgical resection. The surgical techniques of the primary tumor include transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery. Ipsilateral neck dissection should be performed for patients enrolled in this group. For patients with OPC at or approaching the midline, bilateral neck dissection should be strongly considered.

Postoperative radiotherapy (RT) or system therapy/RT should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, or vascular invasion).

Surgery for advanced OPC

The treatment strategy for patients should be discussed by the multidisciplinary team with the goal of maximizing survival with preservation of appearance and function and planned based on the tumor extension as ascertained by clinical evaluation and careful interpretation of appropriate imaging examinations.

Advanced OPC patients (T1-2,N1-3/T3-4,N0-3) enrolled in this group will be treated with neoadjuvant treatment. The subsequent treatments include RT, system therapy/RT, and surgical resection with or without postoperative adjuvant therapy.

Neoadjuvant treatment for advanced OPC

Lei Tao, Dr.

Xiaoke Zhu

This is a prospective, observational study evaluating the effect and efficiency of different clinical treatments for patients with oropharyngeal carcinoma (OPC). The selection of treatment for individual patient is based on tumor characteristics (tumor size and tumor location), a complete assessment of therapeutic effects (treatment effectiveness, possible dysfunction after operation, function maintenance, complications, etc.), and the preferences of doctors and patients.

For early-stage oropharyngeal carcinoma (T1-2,N0), radiotherapy or resection of the primary tumor (transoral laser microsurgery, transoral robotic surgery, conventional transoral surgery, and open surgery) with ipsilateral or bilateral neck dissection are performed according to the guidelines of Chinese society of clinical oncology (CSCO, version 2021) and the NCCN guidelines (version 2021). Postoperative radiotherapy (RT) or chemoradiotherapy (CRT) should be considered for patients with adverse features (e.g., extranodal extension, positive margins, perineural invasion or vascular invasion).

For advanced oropharyngeal carcinoma (T1-2,N1-3/T3-4,N0-3), chemoradiotherapy (CRT), resection of the primary tumor (transoral robotic surgery, conventional transoral surgery, transoral laser microsurgery, and open surgery) with ipsilateral or bilateral neck dissection or neoadjuvant therapy with appropriate therapy (surgical resection, RT or CRT) are performed according to the CSCO guidelines (version 2021) and the NCCN guidelines (version 2021). Postoperative radiotherapy (RT) or chemoradiotherapy (CRT) should be considered for patients with adverse features (e.g., pT3 or pT4 primary, pN2 or pN3 nodal disease, extranodal extension, positive margins, perineural invasion or vascular invasion).

This study aims to evaluate and compare the clinical outcomes of different medical treatments in patients with same TNM stage disease, overall and stratified by HPV expression. Demographic and clinicopathological characteristics of patients enrolled were also collected to assess their associations with treatment strategies and prognoses. The rates of overall survival, disease specific survival, disease free survival, local control, regional control, and progress-free survival are analyzed in the present study.

Whole blood, Tumor tissue (If available), Para-tumor tissue (If available)

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Department of Otorhinolaryngology, Eye & ENT Hospital

The time between the treatment and the date of death from any causes

The time between the treatment and the first evidence of local recurrence

The time between the treatment and the first evidence of regional recurrence

The time between the treatment and the date of death from oropharyngeal cancer

The time between the treatment and the first evidence of disease recurrence, metastasis or death from any cause

The time between the treatment and the date of first documented disease progression or death from any cause

Quality of life as assessed with the MD Anderson Dysphagia Inventory (MDADI)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cell-free Tumor DNA in Head and Neck Cancer Patients	NCT03942380	Head and Neck C... Head and Neck N... Head and Neck S... Oropharynx Canc... Oropharynx Neop... Oropharynx Carc... Oral Cavity Can... Oral Cancer Oral Neoplasm Larynx Cancer Larynx Carcinom... Larynx Neoplasm Nasopharyngeal ... Nasopharyngeal ... Nasopharynx Neo... Hypopharynx Can... Hypopharynx Neo... Hypopharynx Car... Sinonasal Carci... Thyroid Carcino... Thyroid Cancer Thyroid Neoplas... Salivary Gland ... Salivary Gland ... Salivary Gland ... Sinonasal Cance... Sinonasal Neopl...	Liquid biopsy	18 Years -	Rigshospitalet, Denmark
An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma	NCT05341479	Oropharynx Carc...	Surgery for ear... RT for early-st... CRT for advance... Surgery for adv... Neoadjuvant tre...	18 Years - 90 Years	Eye & ENT Hospital of Fudan University
Cell-free Tumor DNA in Head and Neck Cancer Patients	NCT03942380	Head and Neck C... Head and Neck N... Head and Neck S... Oropharynx Canc... Oropharynx Neop... Oropharynx Carc... Oral Cavity Can... Oral Cancer Oral Neoplasm Larynx Cancer Larynx Carcinom... Larynx Neoplasm Nasopharyngeal ... Nasopharyngeal ... Nasopharynx Neo... Hypopharynx Can... Hypopharynx Neo... Hypopharynx Car... Sinonasal Carci... Thyroid Carcino... Thyroid Cancer Thyroid Neoplas... Salivary Gland ... Salivary Gland ... Salivary Gland ... Sinonasal Cance... Sinonasal Neopl...	Liquid biopsy	18 Years -	Rigshospitalet, Denmark

Spots Global Cancer Trial Database for oropharynx carcinoma